Display options
Cite
Nouri M, Ahmadi A, Etezadi F, et al. Comparison of the Effects of Subcutaneous Versus Continuous Infusion of Heparin on Key Inflammatory Parameters Following Sepsis. Anesth Pain Med. 2016;6(2):e33780doi: 10.5812/aapm.33780.
Nouri, M., Ahmadi, A., Etezadi, F., Barzegar, E., & Mojtahedzadeh, M. (2016). Comparison of the Effects of Subcutaneous Versus Continuous Infusion of Heparin on Key Inflammatory Parameters Following Sepsis. Anesthesiology and pain medicine, 6(2), e33780. https://doi.org/10.5812/aapm.33780
Nouri, Masoumeh, et al. "Comparison of the Effects of Subcutaneous Versus Continuous Infusion of Heparin on Key Inflammatory Parameters Following Sepsis." Anesthesiology and pain medicine vol. 6,2 (2016): e33780. doi: https://doi.org/10.5812/aapm.33780
Nouri M, Ahmadi A, Etezadi F, Barzegar E, Mojtahedzadeh M. Comparison of the Effects of Subcutaneous Versus Continuous Infusion of Heparin on Key Inflammatory Parameters Following Sepsis. Anesth Pain Med. 2016 Apr 02;6(2):e33780. doi: 10.5812/aapm.33780. eCollection 2016 Apr. PMID: 27252904; PMCID: PMC4886623.
Copy Download .nbib Format: NLM
Share it on

Anesth Pain Med. 2016 Apr 02;6(2):e33780. doi: 10.5812/aapm.33780. eCollection 2016 Apr.

Comparison of the Effects of Subcutaneous Versus Continuous Infusion of Heparin on Key Inflammatory Parameters Following Sepsis.

Anesthesiology and pain medicine

Masoumeh Nouri, Arezoo Ahmadi, Farhad Etezadi, Elchin Barzegar, Mojtaba Mojtahedzadeh

Affiliations

  1. Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  2. Department of Anesthesiology and Critical Care Medicine, Faculty of Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.

PMID: 27252904 PMCID: PMC4886623 DOI: 10.5812/aapm.33780

Abstract

BACKGROUND: Sepsis is the result of the interaction between inflammatory mediators and coagulation pathway. Unfractionated heparin may play a role as an anti-inflammatory agent beyond its anticoagulatory effect in sepsis. As a result, it may cause reduction in organ failure rate in patients with sepsis due to its impact on both inflammatory and coagulation process.

OBJECTIVES: The aim of this study was to evaluate the anti-inflammatory effects of heparin in sepsis. Plasma plasminogen activator inhibitor-1 (PAI-1) as an inflammatory mediator and urinary necoutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney injury were investigated.

PATIENTS AND METHODS: This prospective, randomized controlled trial was conducted in a 32-bed intensive care unit. Thirty patients with sepsis were randomized to receive heparin infusion of 500 units/hour or 5000 units of heparin three times a day, subcutaneously. The plasma level of PAI-1 and urinary level of NGAL were determined at day 0, 2 and 7.

RESULTS: The infusion group had a lower plasma PAI-1 level compared to the subcutaneous group at day 7 (11.3 ± 1.6 vs. 16.5 ± 4.2; P = 0.003). The urinary NGAL level was lower in the infusion group at day 2 (131.3 ± 11.9 vs. 151.2 ± 20.6; P = 0.014); however, at day 7 the NGAL level was decreased in the subcutaneous group as much as the infusion group and there was no significant difference between the two groups. There was no significant difference in the acute physiology and chronic health evaluation (APACHE) II and sequential organ failure assessment (SOFA) scores between the two groups at day 0, 2 and 7.

CONCLUSIONS: Low-dose heparin infusion compared to subcutaneous heparin can decrease the plasma PAI-1 and urinary NGAL levels more rapidly. It can be related to anti-inflammatory effects of heparin, which may be more prominent in infusion route.

Keywords: Anti-Inflammatory Agents; Heparin; Neutrophil Gelatinase-Associated Lipocalin; Plasminogen Activator Inhibitor 1; Sepsis

References

  1. Thromb Haemost. 2009 Nov;102(5):823-8 - PubMed
  2. Circulation. 2001 Jun 19;103(24):2994-3018 - PubMed
  3. BMC Nephrol. 2015 Feb 13;16:18 - PubMed
  4. J Infect Dev Ctries. 2012 Jul 23;6(7):555-62 - PubMed
  5. Crit Care. 2010;14(5):R182 - PubMed
  6. Exp Ther Med. 2014 Mar;7(3):604-608 - PubMed
  7. Thromb Res. 2012 Mar;129(3):290-5 - PubMed
  8. Crit Care Med. 2008 Nov;36(11):2973-9 - PubMed
  9. J Am Soc Nephrol. 2011 Jun;22(6):999-1006 - PubMed
  10. Crit Care. 2014 Jan 13;18(1):R13 - PubMed
  11. Adv Drug Deliv Rev. 2014 Nov 20;77:3-11 - PubMed
  12. Thromb Res. 2014 Jul;134(1):182-6 - PubMed
  13. Chest. 2012 Feb;141(2 Suppl):e24S-43S - PubMed
  14. Thromb Haemost. 2007 Sep;98 (3):579-86 - PubMed
  15. Crit Care Med. 2015 Mar;43(3):511-8 - PubMed
  16. Crit Care. 2014 Oct 16;18(5):563 - PubMed
  17. Dis Markers. 2013;34(4):237-46 - PubMed
  18. J Biomed Mater Res A. 2003 Aug 1;66(2):376-84 - PubMed
  19. Curr Drug Discov Technol. 2009 Dec;6(4):281-9 - PubMed
  20. Trials. 2006 May 26;7:19 - PubMed
  21. Int J Hematol. 2006 Dec;84(5):398-405 - PubMed
  22. Crit Care Med. 2013 Feb;41(2):580-637 - PubMed

Publication Types